Synonym
NSC 314055; NSC314055; NSC-314055;
IUPAC/Chemical Name
N,N-bis(2-hydroxyethyl)-2-(2-nitro-1H-imidazol-1-yl)acetamide
InChi Key
KGFGBSRVWKBWIC-UHFFFAOYSA-N
InChi Code
InChI=1S/C9H14N4O5/c14-5-3-11(4-6-15)8(16)7-12-2-1-10-9(12)13(17)18/h1-2,14-15H,3-7H2
SMILES Code
OCCN(C(Cn1c([N+]([O-])=O)ncc1)=O)CCO
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
258.23
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: White RA, Workman P, Brown JM. The pharmacokinetics and tumor and neural tissue penetrating properties of SR-2508 and SR-2555 in the dog--hydrophilic radiosensitizers potentially less toxic than misonidazole. Radiat Res. 1980 Dec;84(3):542-61. PMID: 6450431.
2: Rootman J, Gallie B, Kumi C, Bussanich N, Rogers B, Palcic B. Ocular penetration, toxicity, and radiosensitization effects of two hypoxic cell radiosensitizers on retinoblastoma. Arch Ophthalmol. 1986 Nov;104(11):1693-7. doi: 10.1001/archopht.1986.01050230131048. PMID: 2946282.
3: Workman P, Brown JM. Structure-pharmacokinetic relationships for misonidazole analogues in mice. Cancer Chemother Pharmacol. 1981;6(1):39-49. doi: 10.1007/BF00253009. PMID: 7273265.
4: Workman P. Pharmacokinetics of hypoxic cell radiosensitizers: a review. Cancer Clin Trials. 1980 Fall;3(3):237-51. PMID: 7438321.
5: Moldenhauer H, Rose H, Saul G, Wolf G, Kehrberg G. Die Verstärkung der Zytostatikawirkung durch Radiosensitizer--eine Ubersicht zum gegenwärtigen Stand der Chemosensibilisierung [Intensification of cytostatic action by radiosensitizers--a review of the present status of chemosensitization]. Radiobiol Radiother (Berl). 1984;25(2):289-95. German. PMID: 6234615.
6: Sutherland RM, Keng P, Conroy PJ, McDermott D, Bareham BJ, Passalacqua W. In vitro hypoxic cytotoxicity of nitroimidazoles: uptake and cell cycle phase specificity. Int J Radiat Oncol Biol Phys. 1982 Mar-Apr;8(3-4):745-8. doi: 10.1016/0360-3016(82)90726-x. PMID: 7107409.
7: Hirst DG, Hazlehurst JL, Brown JM. Sensitization of normal and malignant tissue to cyclophosphamide by nitroimidazoles with different partition coefficients. Br J Cancer. 1984 Jan;49(1):33-42. doi: 10.1038/bjc.1984.6. PMID: 6229264; PMCID: PMC1976681.
8: Brown JM, Yu NY, Brown DM, Lee WW. SR-2508: a 2-nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical use. Int J Radiat Oncol Biol Phys. 1981 Jun;7(6):695-703. doi: 10.1016/0360-3016(81)90460-0. PMID: 6457018.
9: Astor M, Hall EJ, Biaglow JE, Parham JC. Newly synthesized hypoxia-mediated drugs as radiosensitizers and cytotoxic agents. Int J Radiat Oncol Biol Phys. 1982 Jan;8(1):75-83. doi: 10.1016/0360-3016(82)90388-1. PMID: 7061257.
10: Shrieve DC, Harris JW. The in vitro sensitivity of chronically hypoxic EMT6/SF cells to X-radiation and hypoxic cell radiosensitizers. Int J Radiat Biol Relat Stud Phys Chem Med. 1985 Jul;48(1):127-38. doi: 10.1080/09553008514551131. PMID: 3159699.
11: Siemann DW. Response of murine tumours to combinations of CCNU with misonidazole and other radiation sensitizers. Br J Cancer. 1982 Feb;45(2):272-81. doi: 10.1038/bjc.1982.43. PMID: 6460517; PMCID: PMC2010911.
12: Hall EJ. Oncogenic transformation systems involving mammalian cells in vitro to determine the relative risks of different treatment modalities. Strahlentherapie. 1984 Dec;160(12):725-31. PMID: 6515665.
13: Brown JM, Yu NY. The optimum time for irradiation relative to tumour concentration of hypoxic cell sensitizers. Br J Radiol. 1980 Sep;53(633):915-6. doi: 10.1259/0007-1285-53-633-915. PMID: 7437721.
